RT Journal Article SR Electronic T1 Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.11.20062349 DO 10.1101/2020.04.11.20062349 A1 Daniela Weiskopf A1 Katharina S. Schmitz A1 Matthijs P. Raadsen A1 Alba Grifoni A1 Nisreen M.A. Okba A1 Henrik Endeman A1 Johannes P.C. van den Akker A1 Richard Molenkamp A1 Marion P.G. Koopmans A1 Eric C.M. van Gorp A1 Bart L. Haagmans A1 Rik L. de Swart A1 Alessandro Sette A1 Rory D. de Vries YR 2020 UL http://medrxiv.org/content/early/2020/04/18/2020.04.11.20062349.abstract AB COVID-19 is associated with lymphopenia and ‘cytokine storm’, but no information is available on specific cellular immune responses to SARS-CoV-2. Here, we characterized SARS-CoV-2-specific CD4+ and CD8+ T-cells in patients with acute respiratory distress syndrome. The spike protein (S) proved a potent T-cell antigen and specific T-cells predominantly produced Th1 cytokines. These novel data are important in vaccine design and will facilitate evaluation of vaccine candidate immunogenicity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was not a clinical trial where intervention strategies were tested, rather clinical material from COVID-19 patients were used. Ethical statements are provided in the manuscript.Funding StatementNo dedicated funding was used for acquiring the data presented in this manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this manuscript (and its supplementary information files).